Fetzima 01
Fetzima Kit
Product Images NDC 0456-2202
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Fetzima (NDC 0456-2202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fetzima 02
This is a list of drugs and their interactions. It includes information about drugs that inhibit or induce certain enzymes, such as CYP3A, as well as drugs that act as substrates for these enzymes. The table shows the average maximum concentration (Cmax) and fold change for different drugs, as well as their 90% confidence intervals. However, without additional context or labels, it is difficult to provide specific details about the drugs or their effects.*
Fetzima 03
This appears to be a data table with information on the population's age, gender, renal impairment, and hepatic impairment. It also includes PK data with parameters such as Cmax and AUC, as well as fold change and 90% Cl. Without additional context or a clear indication of what this data pertains to, it is difficult to provide a more specific description.*
Fetzima 04
Fetzima 05
This appears to be a label for the medication Fetzima, a capsule containing 20mg of levomilnacipran hydrochloride which is used to treat depression. The label includes information for storage at 25°C, pricing, and a note to give a medication guide to each patient. The medication is manufactured by Pierre Fabre Medicament and distributed by Allergan.*
Fetzima 06
Each capsule of Fetzima contains 45.9 mg of levomilnacipran. It is an extended-release capsule that should be swallowed whole and not chewed or crushed. It is recommended to store the drug at 25°C (77°F) and keep it away from children. The usual dosage should be taken by following the enclosed guide provided to each patient. The drug is licensed by Allergan and distributed by Allergan USA Inc.*
Fetzima 07
Each capsule of this medication contains 80mg of levominacpran hydrochloride, also identified as Fetzima. It is an extended-release capsule that must be swallowed whole, avoiding chewing or crushing. This medication needs to be stored between 15-30°C (50-86°F), avoiding excessive heat between 25°C (77°F) and controlled room temperature. In case of prescription, it is essential to dispense the accompanying medication guide to each patient. It is a medication marketed by Allergan.*
Fetzima 08
This is a medication called Fetzima, which is an extended-release capsule containing 20mg of levomilnacipran. Each capsule contains 137.8mg of levomilnacipran hycrochlorde equivalent to 120mg of levomilnacipan. The recommended usage and other details can be found in the full prescribing information. The medication guide accompanying the product should be dispensed to each patient. The drug should be swallowed whole and not chewed or crushed. It should be stored at room temperature and kept out of the reach of children. Made in France, licensed from Pere Fabr, and distributed by Allergan USA in Madison, NJ.*
Fetzima 09
This is a description of a product called "Titration Pack", which includes a medication called Fetzima in capsule form. The pack also includes other capsules with the label "Exknded-Kase Capsules", but no further information is provided on what they are for. The Fetzima capsules have a strength of 20mg and there are two types of capsules included: "ey sis & g capsules" and "Pritere Erisreetray" capsules. The product is associated with a company called Allergon.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
